Northern Trust Corp Sells 60,504 Shares of LifeStance Health Group, Inc. $LFST

Key Points

• Northern Trust Corp reduced its stake in LifeStance Health Group by 3.8%, holding 1,531,272 shares valued at approximately $10.2 million after selling 60,504 shares.
• Several hedge funds have increased their investments in LifeStance Health Group, including Victory Capital Management, which raised its holdings by an extraordinary 2,599%.
• LifeStance Health Group's latest earnings report showed a revenue increase of 10.6% year-over-year, with Q2 earnings per share at ($0.01), exceeding estimates of ($0.03).

Northern Trust Corp lessened its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 3.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,531,272 shares of the company's stock after selling 60,504 shares during the period. Northern Trust Corp owned approximately 0.39% of LifeStance Health Group worth $10,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of LFST. Choreo LLC grew its stake in LifeStance Health Group by 6.4% in the 1st quarter. Choreo LLC now owns 27,420 shares of the company's stock worth $183,000 after buying an additional 1,661 shares in the last quarter. Invesco Ltd. grew its stake in LifeStance Health Group by 1.4% in the 1st quarter. Invesco Ltd. now owns 164,384 shares of the company's stock worth $1,095,000 after buying an additional 2,238 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in LifeStance Health Group by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 138,781 shares of the company's stock worth $1,023,000 after buying an additional 3,305 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in LifeStance Health Group in the 1st quarter worth approximately $31,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in LifeStance Health Group by 18.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,740 shares of the company's stock worth $311,000 after buying an additional 7,320 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

Wall Street Analysts Forecast Growth

LFST has been the subject of a number of research reports. UBS Group boosted their price target on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. BTIG Research initiated coverage on shares of LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 price target for the company. Finally, Wall Street Zen raised shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $8.50.

LifeStance Health Group Trading Up 3.3%

LFST traded up $0.17 on Thursday, hitting $5.34. 1,425,662 shares of the company were exchanged, compared to its average volume of 2,326,007. The firm has a fifty day simple moving average of $4.80 and a two-hundred day simple moving average of $5.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. LifeStance Health Group, Inc. has a 12 month low of $3.74 and a 12 month high of $8.61. The stock has a market capitalization of $2.08 billion, a PE ratio of -106.80 and a beta of 1.17.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The business had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. During the same period last year, the company earned ($0.06) EPS. LifeStance Health Group's revenue for the quarter was up 10.6% compared to the same quarter last year. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $18,213,249.99. Following the completion of the sale, the insider owned 14,324,197 shares of the company's stock, valued at $72,623,678.79. This represents a 20.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the sale, the director directly owned 33,524,715 shares of the company's stock, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,407,643 shares of company stock valued at $103,466,750 in the last quarter. Company insiders own 3.20% of the company's stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.